UK cost agency rejects Amgen's virus-based cancer drug
March 16, 2016 at 11:51 AM EDT
LONDON, March 16 (Reuters) - A first-in-class melanoma drug from Amgen based on a tumour-killing virus has been deemed not worth using on Britain's state health service by the country's cost-effectiveness agency NICE.
